Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ImmuneID","sponsor":"Glycomine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"},{"orgOrder":0,"company":"ImmuneID","sponsor":"Alta Partners","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmuneID

    Menu

    ImmuneID

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ImmuneID

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

              Details:

              Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases including GLM101.

              Lead Product(s): GLM101

              Therapeutic Area: Rare Diseases and Disorders Product Name: GLM101

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Glycomine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series B Financing June 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuneID

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

              Details:

              Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alta Partners

              Deal Size: $70.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY